<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00985153</url>
  </required_header>
  <id_info>
    <org_study_id>V221-012</org_study_id>
    <secondary_id>2009_669</secondary_id>
    <nct_id>NCT00985153</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED)</brief_title>
  <official_title>Comparison of the Safety, Tolerability, and Immunogenicity of 3 Consistency Lots of Frozen Measles, Mumps, Rubella, and Varicella Vaccine (ProQuad) in Healthy Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare three consistency lots of ProQuad to each other as well as to M-M-R
      II and Varivax, administered concomitantly at different injection sites, with respect to
      immunogenicity, safety, and tolerability.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2000</start_date>
  <completion_date type="Actual">May 2001</completion_date>
  <primary_completion_date type="Actual">May 2001</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Varicella Antibody Titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer &lt; 1.25 gpELISA units/mL at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 120 mIU/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt; 120 mIU/mL) to Measles at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 10 Ab Units/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt; 10 Ab units/mL) to Mumps at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt; 10 IU/mL) to Rubella at Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Varicella for Subjects Initially With Varicella Antibody Titer &lt; 1.25 gpELISA Units/mL at Baseline - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to Varicella</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Measles for Subjects Initially Seronegative (a Titer &lt; 120 mIU/mL) to Measles at Baseline - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to Measles.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Mumps for Subjects Initially Seronegative (a Titer &lt; 10 Ab Units/mL) to Mumps at Baseline - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to Mumps.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antibody Response to Rubella for Subjects Initially Seronegative (a Titer &lt; 10 IU/mL) to Rubella at Baseline - Geometric Mean Titer</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Postvaccination observed Geometric Mean Titer of antibody to Rubella</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Vaccine-related CAEs</measure>
    <time_frame>6 weeks Postvaccination</time_frame>
    <description>Subjects with a serious vaccine-related CAE (an AE which is assessed by an investigator/qualified physician as being related to study vaccine and results in death, persistent or significant disability/incapacity, prolongs an existing inpatient hospitalization, is life-threatening, a congenital anomaly/birth defect, a cancer, or an overdose).</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">3927</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad Lot 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad Lot 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ProQuad Lot 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>M-M-R II + Varivax</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live</intervention_name>
    <description>A Single 0.5 mL subcutaneous injection at Day 0</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <other_name>ProQuad</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: Varivax</intervention_name>
    <description>A Single 0.5 mL subcutaneous injection at Day 0</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Comparator: M-M-R II</intervention_name>
    <description>A Single 0.5 mL subcutaneous injection at Day 0</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In good health

          -  Negative clinical history of measles, mumps, rubella, varicella, and zoster

        Exclusion Criteria:

          -  Previous receipt of measles, mumps, rubella and/or varicella vaccine either alone or
             in combination

          -  Any immune impairment or deficiency

          -  Exposure to measles, mumps, rubella, varicella, or zoster in the 4 weeks prior to
             vaccination

          -  Vaccination with an inactive vaccine with in the past 14 days

          -  Vaccination with a live vaccine within the past 30 days
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <results_reference>
    <citation>Lieberman JM, Williams WR, Miller JM, Black S, Shinefield H, Henderson F, Marchant CD, Werzberger A, Halperin S, Hartzel J, Klopfer S, Schödel F, Kuter BJ; Consistency Lot Study Group for ProQuad. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody. Pediatr Infect Dis J. 2006 Jul;25(7):615-22.</citation>
    <PMID>16804432</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2009</study_first_submitted>
  <study_first_submitted_qc>September 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2009</study_first_posted>
  <results_first_submitted>January 13, 2010</results_first_submitted>
  <results_first_submitted_qc>January 13, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 9, 2010</results_first_posted>
  <last_update_submitted>November 20, 2015</last_update_submitted>
  <last_update_submitted_qc>November 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>35 clinical sites in the United States and 5 clinical sites in Canada
Date of first participant visit: 12-Apr-2000
Date of last participant visit: 11-May-2001</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ProQuad™ Lot 1</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
        </group>
        <group group_id="P2">
          <title>ProQuad™ Lot 2</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
        </group>
        <group group_id="P3">
          <title>ProQuad™ Lot 3</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
        </group>
        <group group_id="P4">
          <title>M-M-R™ II + VARIVAX™</title>
          <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="985"/>
                <participants group_id="P2" count="968"/>
                <participants group_id="P3" count="962"/>
                <participants group_id="P4" count="1012"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated at Visit 1</title>
              <participants_list>
                <participants group_id="P1" count="985"/>
                <participants group_id="P2" count="968"/>
                <participants group_id="P3" count="962"/>
                <participants group_id="P4" count="1012"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="950"/>
                <participants group_id="P2" count="924"/>
                <participants group_id="P3" count="918"/>
                <participants group_id="P4" count="965"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="44"/>
                <participants group_id="P4" count="47"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="19"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Missed One or More Bleeds</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Incomplete Safety Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ProQuad™ Lot 1</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
        </group>
        <group group_id="B2">
          <title>ProQuad™ Lot 2</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
        </group>
        <group group_id="B3">
          <title>ProQuad™ Lot 3</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
        </group>
        <group group_id="B4">
          <title>M-M-R™ II + VARIVAX™</title>
          <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="985"/>
            <count group_id="B2" value="968"/>
            <count group_id="B3" value="962"/>
            <count group_id="B4" value="1012"/>
            <count group_id="B5" value="3927"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.7" spread="1.3"/>
                    <measurement group_id="B2" value="12.8" spread="1.4"/>
                    <measurement group_id="B3" value="12.7" spread="1.3"/>
                    <measurement group_id="B4" value="12.8" spread="1.4"/>
                    <measurement group_id="B5" value="12.7" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="478"/>
                    <measurement group_id="B2" value="448"/>
                    <measurement group_id="B3" value="442"/>
                    <measurement group_id="B4" value="468"/>
                    <measurement group_id="B5" value="1836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="507"/>
                    <measurement group_id="B2" value="520"/>
                    <measurement group_id="B3" value="520"/>
                    <measurement group_id="B4" value="544"/>
                    <measurement group_id="B5" value="2091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="136"/>
                    <measurement group_id="B4" value="150"/>
                    <measurement group_id="B5" value="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian/Pacific</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="615"/>
                    <measurement group_id="B2" value="630"/>
                    <measurement group_id="B3" value="622"/>
                    <measurement group_id="B4" value="647"/>
                    <measurement group_id="B5" value="2514"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="150"/>
                    <measurement group_id="B2" value="113"/>
                    <measurement group_id="B3" value="116"/>
                    <measurement group_id="B4" value="119"/>
                    <measurement group_id="B5" value="498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Varicella Antibody Titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL</title>
        <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer &lt; 1.25 gpELISA units/mL at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer &lt;1.25 gpELISA units/mL at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ Lot 1</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ Lot 2</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ Lot 3</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O4">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Varicella Antibody Titer ≥ 5 Glycoprotein Enzyme-Linked Immunosorbent Assay (gpELISA) Units/mL</title>
          <description>Antibody Response to Varicella at 6 Weeks Postvaccination for Subjects Initially With Varicella Antibody Titer &lt; 1.25 gpELISA units/mL at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer &lt;1.25 gpELISA units/mL at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="791"/>
                <count group_id="O2" value="761"/>
                <count group_id="O3" value="779"/>
                <count group_id="O4" value="813"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="726"/>
                    <measurement group_id="O2" value="718"/>
                    <measurement group_id="O3" value="736"/>
                    <measurement group_id="O4" value="772"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 120 mIU/mL</title>
        <description>Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt; 120 mIU/mL) to Measles at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ Lot 1</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ Lot 2</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ Lot 3</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O4">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Measles Enzyme-Linked Immunosorbent Assay (ELISA) Antibody Titer ≥ 120 mIU/mL</title>
          <description>Antibody Response to Measles at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt; 120 mIU/mL) to Measles at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
                <count group_id="O2" value="771"/>
                <count group_id="O3" value="779"/>
                <count group_id="O4" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="790"/>
                    <measurement group_id="O2" value="753"/>
                    <measurement group_id="O3" value="753"/>
                    <measurement group_id="O4" value="800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 10 Ab Units/mL</title>
        <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt; 10 Ab units/mL) to Mumps at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ Lot 1</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ Lot 2</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ Lot 3</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O4">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Mumps ELISA Antibody Titer ≥ 10 Ab Units/mL</title>
          <description>Antibody Response to Mumps at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt; 10 Ab units/mL) to Mumps at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="856"/>
                <count group_id="O2" value="823"/>
                <count group_id="O3" value="830"/>
                <count group_id="O4" value="872"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="825"/>
                    <measurement group_id="O2" value="796"/>
                    <measurement group_id="O3" value="788"/>
                    <measurement group_id="O4" value="854"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL</title>
        <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt; 10 IU/mL) to Rubella at Baseline</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ Lot 1</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ Lot 2</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ Lot 3</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O4">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Postvaccination Rubella ELISA Antibody Titer ≥ 10 IU/mL</title>
          <description>Antibody Response to Rubella at 6 Weeks Postvaccination for Subjects Initially Seronegative (a titer &lt; 10 IU/mL) to Rubella at Baseline</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="861"/>
                <count group_id="O2" value="835"/>
                <count group_id="O3" value="836"/>
                <count group_id="O4" value="866"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="852"/>
                    <measurement group_id="O2" value="821"/>
                    <measurement group_id="O3" value="828"/>
                    <measurement group_id="O4" value="859"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Varicella for Subjects Initially With Varicella Antibody Titer &lt; 1.25 gpELISA Units/mL at Baseline - Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to Varicella</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer &lt; 1.25 gpELISA units/mL at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ Lot 1</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ Lot 2</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ Lot 3</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O4">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Varicella for Subjects Initially With Varicella Antibody Titer &lt; 1.25 gpELISA Units/mL at Baseline - Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to Varicella</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, Varicella Antibody Titer &lt; 1.25 gpELISA units/mL at baseline, and followed protocol procedures.</population>
          <units>gpELISA</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="791"/>
                <count group_id="O2" value="761"/>
                <count group_id="O3" value="779"/>
                <count group_id="O4" value="813"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.0" lower_limit="14.9" upper_limit="17.2"/>
                    <measurement group_id="O2" value="18.4" lower_limit="17.2" upper_limit="19.7"/>
                    <measurement group_id="O3" value="19.7" lower_limit="18.4" upper_limit="21.0"/>
                    <measurement group_id="O4" value="17.6" lower_limit="16.6" upper_limit="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Measles for Subjects Initially Seronegative (a Titer &lt; 120 mIU/mL) to Measles at Baseline – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to Measles.</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ Lot 1</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ Lot 2</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ Lot 3</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O4">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Measles for Subjects Initially Seronegative (a Titer &lt; 120 mIU/mL) to Measles at Baseline – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to Measles.</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to measles at baseline, and followed protocol procedures.</population>
          <units>mIU/mL</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="802"/>
                <count group_id="O2" value="771"/>
                <count group_id="O3" value="779"/>
                <count group_id="O4" value="811"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3031.6" lower_limit="2841.6" upper_limit="3234.3"/>
                    <measurement group_id="O2" value="2939.3" lower_limit="2740.0" upper_limit="3153.2"/>
                    <measurement group_id="O3" value="2852.2" lower_limit="2651.0" upper_limit="3068.7"/>
                    <measurement group_id="O4" value="2095.6" lower_limit="1964.2" upper_limit="2235.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Mumps for Subjects Initially Seronegative (a Titer &lt; 10 Ab Units/mL) to Mumps at Baseline – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to Mumps.</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ Lot 1</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ Lot 2</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ Lot 3</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O4">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Mumps for Subjects Initially Seronegative (a Titer &lt; 10 Ab Units/mL) to Mumps at Baseline – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to Mumps.</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to mumps at baseline, and followed protocol procedures.</population>
          <units>ELISA AB units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="856"/>
                <count group_id="O2" value="823"/>
                <count group_id="O3" value="830"/>
                <count group_id="O4" value="872"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.5" lower_limit="94.3" upper_limit="107.2"/>
                    <measurement group_id="O2" value="102.3" lower_limit="96.0" upper_limit="109.0"/>
                    <measurement group_id="O3" value="85.6" lower_limit="79.9" upper_limit="91.8"/>
                    <measurement group_id="O4" value="89.7" lower_limit="84.7" upper_limit="94.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Antibody Response to Rubella for Subjects Initially Seronegative (a Titer &lt; 10 IU/mL) to Rubella at Baseline – Geometric Mean Titer</title>
        <description>Postvaccination observed Geometric Mean Titer of antibody to Rubella</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ Lot 1</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ Lot 2</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ Lot 3</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O4">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Antibody Response to Rubella for Subjects Initially Seronegative (a Titer &lt; 10 IU/mL) to Rubella at Baseline – Geometric Mean Titer</title>
          <description>Postvaccination observed Geometric Mean Titer of antibody to Rubella</description>
          <population>Per-protocol analysis set includes participants who had pre- and postvaccination blood samples within predefined day ranges, were seronegative to rubella at baseline, and followed protocol procedures.</population>
          <units>ELISA AB units</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="861"/>
                <count group_id="O2" value="835"/>
                <count group_id="O3" value="836"/>
                <count group_id="O4" value="866"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.5" lower_limit="107.5" upper_limit="119.8"/>
                    <measurement group_id="O2" value="114.8" lower_limit="108.2" upper_limit="121.8"/>
                    <measurement group_id="O3" value="114.2" lower_limit="108.1" upper_limit="120.6"/>
                    <measurement group_id="O4" value="132.6" lower_limit="125.7" upper_limit="140.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Serious Vaccine-related CAEs</title>
        <description>Subjects with a serious vaccine-related CAE (an AE which is assessed by an investigator/qualified physician as being related to study vaccine and results in death, persistent or significant disability/incapacity, prolongs an existing inpatient hospitalization, is life-threatening, a congenital anomaly/birth defect, a cancer, or an overdose).</description>
        <time_frame>6 weeks Postvaccination</time_frame>
        <population>All subjects with follow-up for safety were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™ Lot 1</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O2">
            <title>ProQuad™ Lot 2</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O3">
            <title>ProQuad™ Lot 3</title>
            <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
          </group>
          <group group_id="O4">
            <title>M-M-R™ II + VARIVAX™</title>
            <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Vaccine-related CAEs</title>
          <description>Subjects with a serious vaccine-related CAE (an AE which is assessed by an investigator/qualified physician as being related to study vaccine and results in death, persistent or significant disability/incapacity, prolongs an existing inpatient hospitalization, is life-threatening, a congenital anomaly/birth defect, a cancer, or an overdose).</description>
          <population>All subjects with follow-up for safety were included in the analysis.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="969"/>
                <count group_id="O2" value="950"/>
                <count group_id="O3" value="941"/>
                <count group_id="O4" value="993"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>With Serious Vaccine-Related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Without Serious Vaccine-Related CAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="967"/>
                    <measurement group_id="O2" value="949"/>
                    <measurement group_id="O3" value="939"/>
                    <measurement group_id="O4" value="992"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Number of participants reported as &quot;At Risk&quot; is the number of participants with follow-up.</desc>
      <group_list>
        <group group_id="E1">
          <title>ProQuad™ Lot 1</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 1 = ProQuad™ containing a varicella dose of 4.40 log10 PFU/0.5 mL.</description>
        </group>
        <group group_id="E2">
          <title>ProQuad™ Lot 2</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 2 administered on Day 0. ProQuad™ Lot 2 = ProQuad™ containing a varicella dose of 4.61 log10 PFU/0.5 mL.</description>
        </group>
        <group group_id="E3">
          <title>ProQuad™ Lot 3</title>
          <description>ProQuad™ (measles, mumps, rubella, and varicella vaccine) Lot 1 administered on Day 0. ProQuad™ Lot 3 = ProQuad™ containing a varicella dose of 4.73 log10 PFU/0.5 mL.</description>
        </group>
        <group group_id="E4">
          <title>M-M-R™ II + VARIVAX™</title>
          <description>VARIVAX™ + M-M-R™ II administered concomitantly at separate injection sites on Day 0.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Merck CRISP</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, urinary tract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Infection, RSV</sub_title>
                <description>Infection, respiratory syncytial virus (RSV)</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Gastroenteritis, Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Infection, viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Accidental ingestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Fracture, humerus, right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Fracture, radius, right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Bite, animal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Drug abuse</sub_title>
                <description>Drug abuse refers to cocaine metabolites found in subject's urine.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Hypovolemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure, febrile</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Seizure disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Hypoxemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Breathing Pattern Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>Merck CRISP</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="793" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="758" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="769" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="785" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Otitis</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="109" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="117" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="80" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="80" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="77" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="81" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="48" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="379" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="362" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="378" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="327" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection, Viral</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="30" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Gastroenteritis, Infectious</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Infection, Respiratory, Upper</sub_title>
                <counts group_id="E1" subjects_affected="280" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="248" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="249" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="245" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Viral Exanthema</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="47" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Trauma</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Bite/Sting, Non-Venomous</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="101" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="119" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Congestion, Nasal</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Congestion, Respiratory</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Laryngotracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="60" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis, Contact</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Miliaria Rubra</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="45" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Rash, Diaper</sub_title>
                <counts group_id="E1" subjects_affected="72" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="80" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="86" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Rash, Measles/Rubella-Like</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Rash, Varicella-Like</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Ecchymosis (ProQuad Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Erythema (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="149" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="163" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="163" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="221" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="246" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="230" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Rash (ProQuad Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Swelling (ProQuad Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="89" subjects_at_risk="969"/>
                <counts group_id="E2" subjects_affected="86" subjects_at_risk="950"/>
                <counts group_id="E3" subjects_affected="86" subjects_at_risk="941"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Ecchymosis (Varivax Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Erythema (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="136" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="262" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Rash (Varivax Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Swelling (Varivax Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="91" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Ecchymosis (M-M-R II Injection-site)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Erythema (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="134" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Pain/Tenderness/Soreness (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="266" subjects_at_risk="993"/>
              </event>
              <event>
                <sub_title>Swelling (M-M-R II Injection-site)</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="80" subjects_at_risk="993"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One additional subject received M-M-R™ II and ProQuad™ vaccines at the same visit in error; this child was excluded from all immunogenicity and safety summaries.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp</organization>
      <phone>1-800-672-6372</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

